Released Feb 11, 2022, after the close
10-K filed Feb 11, 2022, 103 days after period end · 0001654954-22-001532
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.60M$5.60M derived+11.4% vs Q4 2020+12.2% vs Q3 2021
Net Income-$4.87M-$4.87M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$1,498,919+10.4%
Operating Incomederived-$4,798,084N/M
Operating Cash Flowderived$960,350+185.5%
Free Cash Flowderived$961,231+191.2%
Margins · derived
Gross margin26.8%−0.2 pt vs Q4 2020
Operating margin-85.7%−88.7 pt vs Q4 2020
Net margin-87.1%−89.9 pt vs Q4 2020
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.60M | $5.03M | $4.82M | $5.67M |
| Net Income | -$4.87M | $144.35K | $477.60K | $3.34M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR